Jessica Donington to Combined Modality Therapy
This is a "connection" page, showing publications Jessica Donington has written about Combined Modality Therapy.
Connection Strength
0.710
-
Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 06; 165(6):1949-1953.
Score: 0.167
-
The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer. Curr Treat Options Oncol. 2019 03 14; 20(4):27.
Score: 0.130
-
Surgical approach to locally advanced non-small cell lung cancer. Cancer J. 2013 May-Jun; 19(3):217-21.
Score: 0.086
-
Management of early stage non-small cell lung cancer in high-risk patients. Thorac Surg Clin. 2012 Feb; 22(1):55-65, vi.
Score: 0.078
-
The role of surgery in the treatment of stage III non-small-cell lung cancer. Curr Oncol Rep. 2007 Jul; 9(4):247-54.
Score: 0.058
-
Management of locally advanced non small cell lung cancer from a surgical perspective. Curr Treat Options Oncol. 2007 Feb; 8(1):1-14.
Score: 0.056
-
Preoperative chemoradiation therapy does not improve early survival after esophagectomy for patients with clinical stage III adenocarcinoma of the esophagus. Ann Thorac Surg. 2004 Apr; 77(4):1193-8; discussion 1198-9.
Score: 0.046
-
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. J Thorac Oncol. 2016 06; 11(6):900-9.
Score: 0.026
-
Use of photodynamic therapy for the management of pleural malignancies. Semin Surg Oncol. 1995 Sep-Oct; 11(5):360-7.
Score: 0.025
-
Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer. Clin Lung Cancer. 2011 Sep; 12(5):280-5.
Score: 0.019
-
Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 2011 May; 6(5):920-6.
Score: 0.019